Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. - Wikidata - awgldk - TriplyDB

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

http://www.wikidata.org/entity/Q37357439

about

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders Retargeting the management of hypercholesterolemia - focus on evolocumab Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Cholesterol Management in the Era of PCSK9 Inhibitors.Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.Prediction of cardiovascular risk in patients with familial hypercholesterolaemia.Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.PCSK9 inhibitor valuation: A science-based review of the two recent models.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

P2860

Q28070296-A7140ACA-FDFF-4CF1-A8A8-C3D94F074BC2 Q28077289-46DB9289-CF83-4DF0-91A7-53535C3A80F2 Q36247530-3232E7B6-B4A7-4A04-9875-D97BF9C4B70A Q38612448-8B9F668D-92BA-4D10-81DE-895E5E16C6A6 Q38639580-89D59CBE-4D00-4F10-A5FE-922915FE1C86 Q38690757-46A7CDE1-099D-4686-A4FE-B9AE9841F302 Q38965138-EA81D321-6178-48E6-906F-B5E06D4F5E9E Q46077572-20494F01-76F0-4363-A594-13A54A585206 Q46505421-E72D2712-E5B3-4FA5-B1C4-74891D135DC6 Q47392228-55DA13AD-A871-4C06-982D-36B2D6C304F7 Q47643635-4FF784F6-C883-49BE-B5CC-B8E55E7CADF6 Q48520042-0F85B8BD-A68C-44F2-9C8E-F92393D418B5 Q48570562-839F8B8F-F11C-4569-9EF1-F6711D9A15A6 Q51329562-9D02828A-15AA-4E7C-94DA-2BB61217ED30 Q52364662-03B2FDAA-A445-4959-9BBF-02B01A345AA7 Q55476982-9F0B3CA0-0F6A-45E7-8E2B-7006F3E989CE

P2860

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

http://www.wikidata.org/entity/Q37357439

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@en

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@nl

type

label

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@en

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@nl

prefLabel

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@en

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@nl

P1433

Q37357439-9C5F8447-2068-4669-933C-502496532B3C

P1476

Q37357439-E0921E06-EAB5-4EED-8F48-5710A87C9448

P2093

Q37357439-2770B971-8AFC-460D-9BA8-FDD8A212E7C5

Q37357439-839E73FD-A89E-4F8B-AADB-5D525100A2EA

Q37357439-9274DC3D-21BB-4FDA-97BD-56D1DB100D8D

Q37357439-9F563D4E-F5B0-46EF-B0F4-AF97B9717E03

Q37357439-B59D93C3-DCE8-4596-82BE-26F754ECD907

Q37357439-FAFD627B-0BC7-4751-B28A-774CB6DCBEF8

P2860

Q37357439-0230D676-4480-4505-B387-41FD13383C5D

Q37357439-052006CA-3FD1-4CFC-8AC8-C41C0F636AE3

Q37357439-19D0D1D9-6F94-4DAD-83BB-E51693758CEE

Q37357439-1A1C41AC-4C2F-41D9-9244-2DBD6D1224DC

Q37357439-2886A79A-33B8-4CCC-8CB3-8E310D68BB44

Q37357439-3606B20D-5629-4FEE-B6EB-2BFF3B49B39E

Q37357439-38A700EC-F269-4B9A-99FC-F7555EBF0974

Q37357439-3E324B3C-8F44-4422-95FD-F77AF9DCE2C3

Q37357439-577E1EEA-C631-4C04-8404-801E1097D5D3

Q37357439-5823BDED-F644-48A3-A15C-2BF8F4E54862

P304

Q37357439-668D0292-CD16-4C5B-8505-0F0670CEE02F

P31

Q37357439-0a4ab7f7-824a-4843-a1de-2f622c4201a0

Q37357439-131DAF37-07DB-4085-9EDB-99C1C251D8D5

P356

Q37357439-6A52CFE1-4390-4676-8964-95D130765723

P433

Q37357439-D16A4937-4B68-402B-AEC4-9BA1287436AF

P478

Q37357439-A62CC4E1-FE3C-4EAC-BAC9-996912E57BBA

P50

Q37357439-956E1EA2-6FDF-4CAE-86EF-A7067C1E785C

P577

Q37357439-16EB1FD0-5C0C-4146-8A58-9DDA0497C8C6

P698

Q37357439-808ECB60-6EFC-46DA-B6E9-75EDC4BF5E2B

P921

Q37357439-59CF4AA7-2BC9-474D-87D6-6E6B0B9DC384

Q37357439-FCF427B1-BF66-43F7-8429-BBECF3DD6B73

P932

Q37357439-FBC8DFC1-BE7F-40E1-AFBC-C760BB00A234

P356

P1433

Clinical Cardiology

P1476

Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.

@en

P2093

Ben van Hout

http://www.w3.org/2001/XMLSchema#string

Guillermo Villa

http://www.w3.org/2001/XMLSchema#string

Mickael Lothgren

http://www.w3.org/2001/XMLSchema#string

Peter Lindgren

http://www.w3.org/2001/XMLSchema#string

Ransi Somaratne

http://www.w3.org/2001/XMLSchema#string

Shravanthi R Gandra

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Acute and chronic impact of cardiovascular events on health state utilities.

P304

313-320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CLC.22535

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Gregg C. Fonarow

P577

2016-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27092712

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

Ameeriga Ütisriigiq

P932

5074319

http://www.w3.org/2001/XMLSchema#string